22526-30-3

Usage

Preparation

Preparation by Fries rearrangement of 3,4-dichlorophenyl acetate with aluminium chloride without solvent between 120° and 140°(72–73%),(52%)or at 200°.

Upstream product

• 100246-47-7 7-acetyl-3,4,5-trichloro-tropolone 
• 17847-51-7 3,4-dichlorophenyl acetate 
• 95-77-2 3,4-dichlorophenol 
• 75-36-5 acetyl chloride 

Downstream Products

• 35504-03-1 4,5-Dichloro-2-(1-hydroxy-ethyl)-phenol 
• 126235-13-0 1-(4,5-Dichloro-2-hydroxy-phenyl)-3-dimethylamino-propan-1-one; hydrochloride 
• 85128-38-7 4,5-Dichloro-2-(1-imidazol-1-yl-vinyl)-phenol 
• 50274-58-3 4,5-dichloro-2-hydroxybenzoic acid 
• 111477-92-0 1-(2-hydroxy-4,5-dichlorophenyl)-1,3-butandione 
• 2164-37-6 6,7-dichloro-2-hydroxymethyl-1,4-benzodioxane 
• 1382997-69-4 1-(4,5-dichloro-3-iodo-2-methoxyphenyl)ethanone 
• 1382997-67-2 1-(4,5-dichloro-2-hydroxy-3-iodophenyl)ethanone 
• 27407-06-3 6,7-dichloro-4-chromanone 

Relevant academic research and scientific papers

3-(Benzodioxan-2-ylmethoxy)-2,6-difluorobenzamides bearing hydrophobic substituents at the 7-position of the benzodioxane nucleus potently inhibit methicillin-resistant Sa and Mtb cell division

Lipophilic substituents at benzodioxane C (7) of 3-(benzodioxan-2-ylmethoxy)-2,6-difluorobenzamide improve the antibacterial activity against methicillin-resistant Staphylococcus aureus strains to MIC values in the range of 0.2-2.5 μg/mL, whereas hydrophi

USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS

The present application provides methods of treating PI3Kδ related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.

PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS

The present invention provides pyrimidine-4,6-diamine derivatives of Formula (I): wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activit

SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.

Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: Assessment of potency, efficacy, and cardiovascular safety

Evaluation of multiple structurally distinct series of melanin concentrating hormone receptor 1 antagonists in an anesthetized rat cardiovascualar assay led to the identification of a chromone-2-carboxamide series as having excellent safety against the chosen cardiovascular endpoints at high drug concentrations in the plasma and brain. Optimization of this series led to considerable improvements in affinity, functional potency, and pharmacokinetic profile. This led to the identification of a 7-fluorochromone-2-carboxamide (22) that was orally efficacious in a diet-induced obese mouse model, retained a favorable cardiovascular profile in rat, and demonstrated dramatic improvement in effects on mean arterial pressure in our dog cardiovascular model compared to other series reported by our group. However, this analogue also led to prolongation of the QT interval in the dog that was linked to affinity for hERG channel and unexpectedly potent functional blockade of this ion channel.

Biguanide and dihydrotriazine derivatives

Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the

Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them

Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or a diagnostic, and medicament comprising them Chromans of the formula I and of the formula 1a having the meanings R(A), R(B), R(C) and R(1) to R(8) indicated in the claims are outstandingly suitable for preparing a medicament for blocking the K+channel which is opened by cyclic adenosine monophosphate (cAMP); and further for preparing a medicament for inhibiting gastric acid secretion; for the treatment of ulcers of the stomach and of the intestinal region, in particular of the duodenum, for the treatment of reflux esophagitis, for the treatment of diarrheal illnesses, for the treatment and prevention of all types of arrhythmias including ventricular and supraventricular arrhythmias, and for the control of reentry arrhythmias and for the prevention of sudden heart death as a result of ventricular fibrillation.

Hydroxyacetic acid derivatives for the treatment of diabetic complications

Racemic and chiral (2R,4R)-4-c-hydroxy-2-4-(substituted)chroman(and thiochroman)-4-acetic acids and their pharmaceutically acceptable salts, their use in the treatment of diabetic complications and intermediates therefor.

Reductive Dechlorination of Chloro-phenols and -benzoic acids by Raney Co-Al Alloy in an Alkaline Deuterium Oxide Solution and Preparation of Deuterated Salicylic Acids

Reduction of monochloro-phenols (1a-c) and -benzoic acids (3a-c) by using Raney Co-Al alloy in 10percent NaOD-D2O gave phenols (2a-c) and benzoic acids (4a-c) in 86-93percent isotopic purities.The reduction of di-, tri-, and tetra-chlorinated derivatives, (1) and (3), gave the deuteriated products, (2) and (4), in somewhat low isotopic purities (70-84percent).In the reduction of polychlorinated benzoic acids (3), the use of a mixed solution (1/1 = v/v) of 10percent Na2CO3-D2O and 10percent NaOD-D2O was effective and gave 4 in 80-89percent isotopic purities.The treatment of chlorosalicylic acids (5) with Raney Co-Al alloy in 10percent NaOD-D2O gave 1> (6) - 3> (6) in 91-93percent isotopic purities.